- Home
- GTEC vs LSTA Comparison
GTEC vs LSTA Comparison
Compare GTEC & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | LSTA |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 20.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GTEC | LSTA |
|---|---|---|
| Price | $1.07 | $2.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 219.0K | 23.4K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | $1,070,000.00 |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $1.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $1.81 |
| 52 Week High | $2.92 | $4.20 |
Technical Indicators
Market Signals| Indicator | GTEC | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 45.08 |
| Support Level | $1.02 | $1.97 |
| Resistance Level | $1.09 | $2.15 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 58.24 | 51.87 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.